Low dose intravenous iloprost therapy in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 426s Year: 2006
Pulmonary hemodynamics in highlanders with high altitude pulmonary hypertension in 1 year after finishing of sildenafil treatment Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy Year: 2005
Long-term treatment with oral sildenafil in addition to chronic prostacyclin therapy improves pulmonary hemodynamics and six minute walking test in patients with pulmonary arterial hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 598s Year: 2002
Acetazolamide and chronic hypoxia: effects on haemorheology and pulmonary haemodynamics Source: Eur Respir J 2012; 40: 1401-1409 Year: 2012
Reversibility of increased intrathoracic gas volume and decreased compliance in infants with pulmonary hyperperfusion and hypertension after repair of congenital heart disease Source: Eur Respir J 2005; 26: Suppl. 49, 675s Year: 2005
High prevalence of iron deficiency in idiopathic pulmonary arterial hypertension Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008
Acute effects of oxygen supplementation during exercise in patients with pulmonary arterial hypertension Source: International Congress 2019 – Exercise physiopathology in various respiratory diseases Year: 2019
Effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise Source: Eur Respir J 2001; 18: Suppl. 33, 324s Year: 2001
Effects of oxygen supplementation during exercise on hemodynamic responses in patients with pulmonary arterial hypertension Source: Virtual Congress 2020 – New insights into evaluation and treatment of respiratory disease Year: 2020
Dexamethasone and tadalafil prophylaxis prevents both excessive pulmonary constriction and high altitude pulmonary edema in susceptible subjects Source: Eur Respir J 2004; 24: Suppl. 48, 110s Year: 2004
Effect of riociguat on pulmonary arterial compliance (PAC) in patients with PAH in PATENT-1 Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015
Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension Source: Eur Respir J 2001; 17: 14-19 Year: 2001
LATE-BREAKING ABSTRACT: Peak oxygen consumption improves in inoperable, but not operable, chronic thromboembolic pulmonary hypertension after treatment with pulmonary arterial hypertension drugs Source: Annual Congress 2013 –New physiologic boundaries Year: 2013
Hypoxic pulmonary hypertension in man: what minimum daily duration of hypoxaemia is required? Source: Eur Respir J 2001; 18: 251-253 Year: 2001
Comparison of exercise capacity and exercise haemodynamic relationships between severe group 3 pulmonary hypertension and pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016
The effects of beta-blocker therapy on heart rate, symptoms and exercise in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013
Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006
Effect of intravenous epoprostenol on quality of life in pulmonary arterial hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 563s Year: 2003
Cardiac function during exercise in pulmonary arterial hypertension Source: Annual Congress 2005 - Exercise in pulmonary hypertension Year: 2005
Amelioration of right ventricular morphology and systolic function in patients with severe group 3 pulmonary hypertension treated with pulmonary vasodilators Source: International Congress 2015 – Pulmonary hypertension in lung disease Year: 2015